Rebecca Henderson - Amgen Insider

Amgen Inc -- USA Stock  

USD 170.12  0.16  0.0941%

Independent Director

Dr. Rebecca M. Henderson, Ph.D., is an Independent Director of Amgen Inc. Rebecca M. Henderson was the John and Natty McArthur University Professor at Harvard University since 2011. From 2009 to 2011, Dr. Henderson served as the Senator John Heinz Professor of Environmental Management at Harvard Business School. Prior to this, she was a professor of management at the Massachusetts Institute of Technology, or MIT, for 21 years, having been the Eastman Kodak LFM Professor of Management since 1999. Since 1995, she has also been a Research Associate at the National Bureau of Economic Research. She specializes in technology strategy and the broader strategic problems faced by companies in high technology industries. Dr. Henderson was a director of IDEXX Laboratories, Inc., a company which provides diagnostic and information technologybased products and services for veterinary, food and water applications, since 2003, chairing its Finance Committee and serving on its Nominating and Governance Committee. Dr. Henderson has also served as a director of the Ember Corporationrationration, a privatelyheld semiconductor chip manufacturer, and on its Compensation Committee, from 2001 to July 2009. She has further been a director of Linbeck Construction Corporationrationration, a privatelyheld facility solutions company, from 2000 until 2004. Dr. Henderson has published articles, papers and reviews in a range of scholarly journals
Age: 55  Director Since 2009  Ph.D    
805 447-1010  www.amgen.com
Henderson received an undergraduate degree from MIT and a doctorate from Harvard University.

Rebecca Henderson Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.27 % which means that it generated profit of $8.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 26.43 % meaning that it created $26.43 on every $100 dollars invested by stockholders.
The company currently holds 35.06 B in liabilities with Debt to Equity (D/E) ratio of 110.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 6.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Nancy HutsonEndo International plc
2009
W FarrellAbbott Laboratories
2006
Ronald TaylorAllergan plc
2013
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Robert MalchioneBio Rad Laboratories Inc
2014
Christopher BodineAllergan plc
2013
Fred WeissAllergan plc
2013
Todd SisitskyEndo International plc
2016
Roxanne AustinAbbott Laboratories
2000
Sally BlountAbbott Laboratories
2011
William MontagueEndo International plc
2009
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Sharad MansukaniEndo International plc
2017
Christopher CoughlinAllergan plc
2016
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Nancy McKinstryAbbott Laboratories
2011
Deborah NeffBio Rad Laboratories Inc
2011
Joel McCombBio Rad Laboratories Inc
2014
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Shane CookeEndo International plc
2014
Robert AlpernAbbott Laboratories
2008

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 17,900 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run ETF Directory Now
   

ETF Directory

Find actively-traded Exchange Traded Funds (ETF) from around the world
Hide  View All  NextLaunch ETF Directory
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
R Williams, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators